Pneumonia Vaccine Market by Product Type and Application- Global Industry Analysis & Forecast to 2027
Published On : September 2020 Pages : 151 Category: Pharma & Healthcare Report Code : HC0912721
Pneumonia Vaccine Market By Product Type (Pneumococcal Conjugate Vaccine (PCV13) ,Pneumococcal Polysaccharide Vaccine (PPSV23) and Application (Pneumonia , Meningitis , Sepsis) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Pneumonia Vaccine Markethas encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Pneumonia Vaccine is the antibacterial vaccine to prevent bacterium Streptococcus pneumonia and it consists of capsular polysaccharides covalently bound to the diphtheria toxoid CRM197, which is highly immunogenic but non-toxic.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Pneumonia Vaccine Marketsize market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- GlaxoSmithKline
- Pfizer
- Merck
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Pneumonia Vaccine Market, By Product Type, Estimates and Forecast, 2017-2027 ($Million)
o Pneumococcal Conjugate Vaccine (PCV13)
o Pneumococcal Polysaccharide Vaccine (PPSV23)
· Pneumonia Vaccine Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Pneumonia
o Meningitis
o Sepsis
· Pneumonia Vaccine Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o GlaxoSmithKline
o Pfizer
o Merck
· Pneumonia Vaccine Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Pneumonia Vaccine Market , By Country
o U.S. Pneumonia Vaccine Market
o Canada Pneumonia Vaccine Market
o Mexico Pneumonia Vaccine Market
o Europe
§ Europe Pneumonia Vaccine Market , By Country
o UK Pneumonia Vaccine Market
o Germany Pneumonia Vaccine Market
o France Pneumonia Vaccine Market
o Russia Pneumonia Vaccine Market
o Italy Pneumonia Vaccine Market
o Rest of Europe Pneumonia Vaccine Market
o Asia-Pacific
§ Asia-Pacific Pneumonia Vaccine Market , By Country
o China Pneumonia Vaccine Market
o Japan Pneumonia Vaccine Market
o South Korea Pneumonia Vaccine Market
o India Pneumonia Vaccine Market
o Southeast Asia Pneumonia Vaccine Market
o Rest of Asia-Pacific Pneumonia Vaccine Market
o South America
§ South America Pneumonia Vaccine Market
o Brazil Pneumonia Vaccine Market
o Argentina Pneumonia Vaccine Market
o Columbia Pneumonia Vaccine Market
o Rest of South America Pneumonia Vaccine Market
o Middle East and Africa
§ Middle East and Africa Pneumonia Vaccine Market
o Saudi Arabia Pneumonia Vaccine Market
o UAE Pneumonia Vaccine Market
o Egypt Pneumonia Vaccine Market
o Nigeria Pneumonia Vaccine Market
o South Africa Pneumonia Vaccine Market
o Rest of MEA Pneumonia Vaccine Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Pneumonia Vaccine Market, By Product Type
5.1. Introduction
5.2. Global Pneumonia Vaccine Revenue and Market Share by Product Type (2017-2021)
5.2.1. Global Pneumonia Vaccine Revenue and Revenue Share by Product Type (2017-2021)
5.3. Pneumococcal Conjugate Vaccine (PCV13)
5.3.1. Global Pneumococcal Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2021)
5.4. Pneumococcal Polysaccharide Vaccine (PPSV23)
5.4.1. Global Pneumococcal Polysaccharide Vaccine (PPSV23) Revenue and Growth Rate (2017-2021)
6. Pneumonia Vaccine Market, By Applications
6.1. Introduction
6.2. Global Pneumonia Vaccine Revenue and Market Share by Applications (2017-2021)
6.2.1. Global Pneumonia Vaccine Revenue and Revenue Share by Applications (2017-2021)
6.3. Pneumonia
6.3.1. Global Pneumonia Revenue and Growth Rate (2017-2021)
6.4. Meningitis
6.4.1. Global Meningitis Revenue and Growth Rate (2017-2021)
6.5. Sepsis
6.5.1. Global Sepsis Revenue and Growth Rate (2017-2021)
7. Pneumonia Vaccine Market, By Region
7.1. Introduction
7.2. Global Pneumonia Vaccine Revenue and Market Share by Regions
7.2.1. Global Pneumonia Vaccine Revenue by Regions (2017-2021)
7.3. North America Pneumonia Vaccine by Countries
7.3.1. North America Pneumonia Vaccine Revenue and Growth Rate (2017-2021)
7.3.2. North America Pneumonia Vaccine Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Pneumonia Vaccine by Countries
7.4.1. Europe Pneumonia Vaccine Revenue and Growth Rate (2017-2021)
7.4.2. Europe Pneumonia Vaccine Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Pneumonia Vaccine by Countries
7.5.1. Asia-Pacific Pneumonia Vaccine Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Pneumonia Vaccine Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Pneumonia Vaccine by Countries
7.6.1. South America Pneumonia Vaccine Revenue and Growth Rate (2017-2021)
7.6.2. South America Pneumonia Vaccine Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Pneumonia Vaccine by Countries
7.7.1. Middle East and Africa Pneumonia Vaccine Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Pneumonia Vaccine Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. GlaxoSmithKline
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Pfizer
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Merck
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
9. Pneumonia Vaccine Market Forecast (2022-2027)
9.1. Global Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Pneumonia Vaccine Market Forecast by Regions (2022-2027)
9.2.1. North America Pneumonia Vaccine Market Forecast (2022-2027)
9.2.1.1. United States Pneumonia Vaccine Market Forecast (2022-2027)
9.2.1.2. Canada Pneumonia Vaccine Market Forecast (2022-2027)
9.2.1.3. Mexico Pneumonia Vaccine Market Forecast (2022-2027)
9.2.2. Europe Pneumonia Vaccine Market Forecast (2022-2027)
9.2.2.1. Germany Pneumonia Vaccine Market Forecast (2022-2027)
9.2.2.2. France Pneumonia Vaccine Market Forecast (2022-2027)
9.2.2.3. UK Pneumonia Vaccine Market Forecast (2022-2027)
9.2.2.4. Russia Pneumonia Vaccine Market Forecast (2022-2027)
9.2.2.5. Italy Pneumonia Vaccine Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Pneumonia Vaccine Market Forecast (2022-2027)
9.2.3. Asia-Pacific Pneumonia Vaccine Market Forecast (2022-2027)
9.2.3.1. China Pneumonia Vaccine Market Forecast (2022-2027)
9.2.3.2. Japan Pneumonia Vaccine Market Forecast (2022-2027)
9.2.3.3. Korea Pneumonia Vaccine Market Forecast (2022-2027)
9.2.3.4. India Pneumonia Vaccine Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Pneumonia Vaccine Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Pneumonia Vaccine Market Forecast (2022-2027)
9.2.4. South America Pneumonia Vaccine Market Forecast (2022-2027)
9.2.4.1. Brazil Pneumonia Vaccine Market Forecast (2022-2027)
9.2.4.2. Argentina Pneumonia Vaccine Market Forecast (2022-2027)
9.2.4.3. Columbia Pneumonia Vaccine Market Forecast (2022-2027)
9.2.4.4. Rest of South America Pneumonia Vaccine Market Forecast (2022-2027)
9.2.5. Middle East and Africa Pneumonia Vaccine Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Pneumonia Vaccine Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Pneumonia Vaccine Market Forecast (2022-2027)
9.2.5.3. Egypt Pneumonia Vaccine Market Forecast (2022-2027)
9.2.5.4. Nigeria Pneumonia Vaccine Market Forecast (2022-2027)
9.2.5.5. South Africa Pneumonia Vaccine Market Forecast (2022-2027)
9.2.5.6. Turkey Pneumonia Vaccine Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Pneumonia Vaccine Market Forecast (2022-2027)
9.3. Pneumonia Vaccine Market Forecast by Product Type (2022-2027)
9.3.1. Pneumonia Vaccine Forecast by Product Type (2022-2027)
9.3.2. Pneumonia Vaccine Market Share Forecast by Product Type (2022-2027)
9.4. Pneumonia Vaccine Market Forecast by Applications (2022-2027)
9.4.1. Pneumonia Vaccine Forecast by Applications (2022-2027)
9.4.2. Pneumonia Vaccine Market Share Forecast by Applications (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Pneumonia Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Pneumonia Vaccine Revenue and Revenue Share by Product Type (2017-2019)
Figure Global Pneumococcal Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2019)
Figure Global Pneumococcal Polysaccharide Vaccine (PPSV23) Revenue and Growth Rate (2017-2019)
Table Global Pneumonia Vaccine Revenue and Revenue Share by Applications (2017-2019)
Figure Global Pneumonia Revenue and Growth Rate (2017-2019)
Figure Global Meningitis Revenue and Growth Rate (2017-2019)
Figure Global Sepsis Revenue and Growth Rate (2017-2019)
Table Global Pneumonia Vaccine Revenue by Regions (2017-2019)
Figure North America Pneumonia Vaccine Growth Rate (2017-2019)
Figure North America Pneumonia Vaccine Revenue and Growth Rate (2017-2019)
Figure North America Pneumonia Vaccine by Countries (2017-2019)
Figure North America Pneumonia Vaccine Revenue (Million USD) by Countries (2017-2019)
Figure United States Pneumonia Vaccine Growth Rate (2017-2019)
Figure United States Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Pneumonia Vaccine Growth Rate (2017-2019)
Figure Canada Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Pneumonia Vaccine Growth Rate (2017-2019)
Figure Mexico Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Pneumonia Vaccine Growth Rate (2017-2019)
Figure Europe Pneumonia Vaccine Revenue and Growth Rate (2017-2019)
Figure Europe Pneumonia Vaccine by Countries (2017-2019)
Figure Europe Pneumonia Vaccine Revenue (Million USD) by Countries (2017-2019)
Figure Germany Pneumonia Vaccine Growth Rate (2017-2019)
Figure Germany Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Pneumonia Vaccine Growth Rate (2017-2019)
Figure France Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Pneumonia Vaccine Growth Rate (2017-2019)
Figure UK Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Pneumonia Vaccine Growth Rate (2017-2019)
Figure Russia Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Pneumonia Vaccine Growth Rate (2017-2019)
Figure Italy Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Pneumonia Vaccine Growth Rate (2017-2019)
Figure Rest of Europe Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Pneumonia Vaccine Growth Rate (2017-2019)
Figure Asia-Pacific Pneumonia Vaccine Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Pneumonia Vaccine by Countries (2017-2019)
Figure Asia-Pacific Pneumonia Vaccine Revenue (Million USD) by Countries (2017-2019)
Figure China Pneumonia Vaccine Growth Rate (2017-2019)
Figure China Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Pneumonia Vaccine Growth Rate (2017-2019)
Figure Japan Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Pneumonia Vaccine Growth Rate (2017-2019)
Figure Korea Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Pneumonia Vaccine Growth Rate (2017-2019)
Figure India Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Pneumonia Vaccine Growth Rate (2017-2019)
Figure Southeast Asia Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Pneumonia Vaccine Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Pneumonia Vaccine Growth Rate (2017-2019)
Figure South America Pneumonia Vaccine Revenue and Growth Rate (2017-2019)
Figure South America Pneumonia Vaccine by Countries (2017-2019)
Figure South America Pneumonia Vaccine Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Pneumonia Vaccine Growth Rate (2017-2019)
Figure Brazil Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Pneumonia Vaccine Growth Rate (2017-2019)
Figure Argentina Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Pneumonia Vaccine Growth Rate (2017-2019)
Figure Columbia Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Pneumonia Vaccine Growth Rate (2017-2019)
Figure Rest of South America Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Pneumonia Vaccine Growth Rate (2017-2019)
Figure Middle East and Africa Pneumonia Vaccine Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Pneumonia Vaccine by Countries (2017-2019)
Figure Middle East and Africa Pneumonia Vaccine Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Pneumonia Vaccine Growth Rate (2017-2019)
Figure Saudi Arabia Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Pneumonia Vaccine Growth Rate (2017-2019)
Figure United Arab Emirates Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Pneumonia Vaccine Growth Rate (2017-2019)
Figure Egypt Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Pneumonia Vaccine Growth Rate (2017-2019)
Figure Nigeria Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Pneumonia Vaccine Growth Rate (2017-2019)
Figure South Africa Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Pneumonia Vaccine Growth Rate (2017-2019)
Figure Turkey Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Pneumonia Vaccine Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Table GlaxoSmithKline Pneumonia Vaccine Financial Overview
Table Pfizer Pneumonia Vaccine Financial Overview
Table Merck Pneumonia Vaccine Financial Overview
Figure Global Pneumonia Vaccine Revenue (Millions USD) and Growth Rate (2019-2027)
Table Pneumonia Vaccine Market Forecast by Regions (2019-2027)
Figure North America Pneumonia Vaccine Market Forecast (2019-2027)
Figure United States Pneumonia Vaccine Market Forecast (2019-2027)
Figure Canada Pneumonia Vaccine Market Forecast (2019-2027)
Figure Mexico Pneumonia Vaccine Market Forecast (2019-2027)
Figure Europe Pneumonia Vaccine Market Forecast (2019-2027)
Figure Germany Pneumonia Vaccine Market Forecast (2019-2027)
Figure France Pneumonia Vaccine Market Forecast (2019-2027)
Figure UK Pneumonia Vaccine Market Forecast (2019-2027)
Figure Russia Pneumonia Vaccine Market Forecast (2019-2027)
Figure Italy Pneumonia Vaccine Market Forecast (2019-2027)
Figure Rest of Europe Pneumonia Vaccine Market Forecast (2019-2027)
Figure Asia-Pacific Pneumonia Vaccine Market Forecast (2019-2027)
Figure China Pneumonia Vaccine Market Forecast (2019-2027)
Figure Japan Pneumonia Vaccine Market Forecast (2019-2027)
Figure Korea Pneumonia Vaccine Market Forecast (2019-2027)
Figure India Pneumonia Vaccine Market Forecast (2019-2027)
Figure Southeast Asia Pneumonia Vaccine Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Pneumonia Vaccine Market Forecast (2019-2027)
Figure South America Pneumonia Vaccine Market Forecast (2019-2027)
Figure Brazil Pneumonia Vaccine Market Forecast (2019-2027)
Figure Argentina Pneumonia Vaccine Market Forecast (2019-2027)
Figure Columbia Pneumonia Vaccine Market Forecast (2019-2027)
Figure Rest of South America Pneumonia Vaccine Market Forecast (2019-2027)
Figure Middle East and Africa Pneumonia Vaccine Market Forecast (2019-2027)
Figure Saudi Arabia Pneumonia Vaccine Market Forecast (2019-2027)
Figure United Arab Emirates Pneumonia Vaccine Market Forecast (2019-2027)
Figure Egypt Pneumonia Vaccine Market Forecast (2019-2027)
Figure Nigeria Pneumonia Vaccine Market Forecast (2019-2027)
Figure South Africa Pneumonia Vaccine Market Forecast (2019-2027)
Figure Turkey Pneumonia Vaccine Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Pneumonia Vaccine Market Forecast (2019-2027)
Figure Global Pneumonia Vaccine Forecast by Product Type (2019-2027)
Figure Global Pneumonia Vaccine Market Share Forecast by Product Type (2019-2027)
Figure Global Pneumonia Vaccine Forecast by Product Type (2019-2027)
Figure Global Pneumonia Vaccine Forecast by Applications (2019-2027)
Figure Global Pneumonia Vaccine Market Share Forecast by Applications (2019-2027)
Figure Global Pneumonia Vaccine Forecast by Applications (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|